Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 907 of 1,261
  1. US 8263661

    Development of new selective estrogen receptor modulators

    The Regents of the University of California · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  2. US 8263650

    Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

    Jazz Pharmaceuticals, Inc. · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  3. US 8263651

    Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors

    The Regents of the University of California · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  4. US 8263662

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  5. US 8263759

    Sets of probes and primers for the diagnosis of select cancers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  6. US 8263747

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  7. US 8263762

    Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists

    Dogwood Pharmaceuticals, Inc. · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  8. US 8263776

    Inhibitors of c-Met protein kinase

    Vertex Pharmaceuticals Incorporated · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  9. US 8263777

    Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase

    Vertex Pharmaceuticals Incorporated · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  10. US 8263095

    Methods of use for peptides having activities of insulin like growth factor-1

    CAREGEN CO., LTD. · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  11. US 8263677

    Removable color gel basecoat for artificial nail coatings and methods therefore

    Creative Nail Design Inc. · Granted Sep 11, 2012 · Expires Sep 6, 2032

    granted
  12. FR 2972192

    COMPOSITION PHARMACEUTIQUE DESTINEE A LA PREVENTION OU AU TRAITEMENT DES CANCERS

    BIOCODEX [FR] · Granted Sep 7, 2012 · Expires Sep 2, 2032

    granted
  13. US 8257699

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    HALOZYME, INC. · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  14. US 8258252

    Sustained-release composition and process for producing the same

    Takeda Pharmaceutical Company Limited · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  15. US 8258163

    Small-molecule agonists for type-2 orexin receptor

    The Board of Regents of the University of Texas System · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  16. US 8258142

    Substituted 8-[6-amino-3-pyridyl]xanthines

    Dogwood Pharmaceuticals, Inc. · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  17. US 8258122

    3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives

    Almirall, S.A. · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  18. US 8257915

    Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  19. US 8258263

    Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  20. US 8258308

    Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors

    Laboratories Almirall, S.A. · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  21. US 8258324

    Intermediates useful in the preparation of maleimide functionalized polymers

    Nektar Therapeutics · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  22. US 8258257

    Claudin-4 binding peptides, compositions and methods of use

    The Regents of the University of California · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  23. US 8258274

    Vaccines containing canine parvovirus genetic variants

    The Board of Regents for Oklahoma State University · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted
  24. US 8258116

    Combination therapy for the treatment of HCV infection

    Vertex Pharmaceuticals Incorporated · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.